The current disclosure provides novel methods and compositions to suppress immunity and are useful for treating autoimmune and inflammatory conditions, and in some circumstances, cancers. Accordingly, aspects of the disclosure relate to a method for treating an inflammatory, autoimmune, autoinflammatory or cancer disease or condition in a subject comprising administering a DUX4 polypeptide or nucleic acid encoding a DUX4 polypeptide to the subject. Further aspects relate to a method for treating a tissue transplant subject, the method comprising administering a DUX4 polypeptide or nucleic acid encoding a DUX4 polypeptide to the subject. The present inventions also relate to universal donor stem cells that overcome immune rejection in cell-based transplantation therapies.
The present disclosure relates to HA-1-targeted T cell receptor (TCR) T cell therapy for treating hematological cancer, such as recurrent leukemia after hematopoietic stem cell transplantation. Provided embodiments include T cell compositions and methods of using the same in therapy, as well as methods of making the compositions. Provided embodiments further include CD8+ T cells made by a method and methods for making CD8+ T cells.
A61K 31/675 - Composés du phosphore ayant l'azote comme hétéro-atome d'un cycle, p. ex. phosphate de pyridoxal
A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p. ex. leucoglucosane, hespéridine, érythromycine, nystatine
A61K 31/7068 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p. ex. cytidine, acide cytidylique
A61K 31/7076 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées contenant des purines, p. ex. adénosine, acide adénylique
A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
A61K 40/22 - Immunosuppresseur ou induisant la tolérance
An antibody against respiratory syncytial virus (RSV) and/or human metapneumovirus (HMPV) is described herein. The antibody includes binding domains from anti-idiotypic monoclonal antibodies (ai-mAbs) that bind an RSV neutralizing antibody VH3-21/VL1-40 presented as B cell receptors (BCRs). The antibodies can be used as a vaccine to selectively elicit antibodies capable of neutralizing RSV and/or HMPV without a need for somatic mutation. The vaccines are particularly useful to treat and/or reduce the risk of RSV and/or HMPV infection in infants.
A61P 31/14 - Antiviraux pour le traitement des virus ARN
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/42 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre des immunoglobulines (anticorps anti-idiotypiques)
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
Novel chimeric and/or humanized forms of the anti-CD45 BC8 antibody are described. The disclosed chimeric or humanized antibodies can be used as research, diagnostic, or therapeutic tools against CD45-related disorders, such as hematologic malignancies including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), other myeloid and lymphoid disorders, other cancers, as well as non-malignant disorders, such as autoimmune disorders, infections, inherited blood disorders, and metabolic disorders.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 51/10 - Anticorps ou immunoglobulinesLeurs fragments
A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie
5.
NOVEL TCRS AND NEOANTIGENS IN SRSF2 AND ZRSR2 MUTATED CANCERS
SRSF2ZRSR2ZRSR2, wherein the mutations are shared across patients with those mutational genotypes, as well as cognate T cell receptors (TCRs) that specifically recognize those neoantigens.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
G16B 25/10 - Profilage de l’expression de gènes ou de protéinesEstimation ou normalisation de ratio d’expression
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
6.
SCLCPHENO-SEQ, A TARGETED CAPTURE PANEL AND ASSOCIATED METHODOLOGY TO CALL THE ACTIVITY OF KEY TRANSCRIPTION FACTORS OF CLINICAL RELEVANCE TO SMALL CELL LUNG CANCER FROM PATIENT LIQUID BIOPSIES
Small cell lung cancer (SCLC) exhibits distinct molecular subtypes characterized by activation of transcription factors (TFs) such as ASCL1, NEUROD1, POU2F3, and REST, but clinical translation has been limited by tissue scarcity. Here, a cell-free DNA (cfDNA) targeted sequencing assay is disclosed that analyzes DNA fragmentation patterns to infer nucleosome profiles at TF binding sites and gene transcription start sites (TSSs) and also detects exonic mutations in certain genes. Application to plasma cfDNA from SCLC patient-derived xenograft models faithfully captured signatures of TF activity and gene expression and revealed a subset of highly informative nucleosome profiling loci including TSSs of key genes including ATOH1, POU2AF2, and targets of SCLC subtype defining TFs. Prediction models of ASCL1, NEUROD1, and REST activity achieved AUCs (0.82-1.00) in SCLC patient samples while a predictor of SCLC vs NSCLC histology achieved an AUC of 0.99. Targeted cfDNA nucleosome profiling can enable SCLC subtyping to improve patient care.
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
G16B 20/30 - Détection de sites de liaison ou de motifs
7.
ANTIBODIES WITH NOVEL FC MODIFICATION COMBINATIONS THAT INCREASE ANTIBODY FUNCTION
Antibodies with novel Fc modification combinations that increase antibody function are described. The novel Fc modification combinations include M252Y/S254T/T256E (YTE) in combination with M428L/N434S (LS) (YTE+LS), YTE+LS in combination with S239D/A330L/I332E (OLE) (YTE+LS+DLE), YTE+LS in combination with G236A/A330L/I332E (YTE+LS+ALE), YTE+LS in combination with G236A/S239D/A330L (DAL) (YTE+LS+DAL) and YTE+LS in combination with G236A/S239D/A330L/I332E (DALE) (YTE+LS+DALE). Glycosylation modifications are optionally included with these combinations.
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
8.
GENE EDITING FOR LATENT HERPES SIMPLEX VIRUS INFECTION REDUCES VIRAL LOAD AND SHEDDING IN VIVO
Embodiments of the present disclosure are directed to methods and compositions for treating recurrent Herpes simplex virus (HSV) disease associated with latent Herpes simplex virus type I(HSV-1) reactivation in a subject. In some embodiments, the composition comprises a plurality of at least three different adeno-associated viral vector (AAV) serotypes, each viral vector serotype comprising a first nucleic acid sequence encoding a first HSV-1-specific meganuclease, and a second nucleic acid sequence encoding a second HSV-1-specific meganuclease, separately. In some embodiments, the composition comprises an adeno-associated viral vector serotype comprising at least one sequence encoding an HSV-1-specific meganuclease targeting a duplicated region of the HSV-1 genome. In certain embodiments the adeno-associated viral vectors disclosed herein further comprise a neuron-specific promoter.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
9.
VACCINES AND COMPOSITIONS AGAINST GAMMA HERPESVIRUSES
The disclosure provides compositions, methods of treatment, and methods of making and using compositions to deliver a nucleic acid to a subject. Compositions described herein include lipid carriers, optionally including an inorganic particle, capable of admixing with nucleic acids. Methods of using these compositions as a vaccine for treatment of a gamma herpesvirus or a cancer are also provided.
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61P 31/20 - Antiviraux pour le traitement des virus ADN
C12N 15/38 - Herpétoviridae, p. ex. virus de l'herpès simplex, herpesvirus varicellae, virus Epstein-Barr, cytomégalovirus, virus de la pseudorage
10.
PROFILING RNA AT CHROMATIN TARGETS IN SITU BY ANTIBODY-TARGETED TAGMENTATION
Embodiments of the present disclosure provide methods and kits for mapping a cellular RNA using a tethered enzyme complex. Embodiments of the method comprise binding a first recognition agent to an epitope of RNA or its associated proteins; binding a second recognition agent that specifically binds to the first recognition agent; and tethering an enzyme complex to the first recognition agent and/or the second recognition agent, wherein the enzyme complex enables reverse transcription to convert a mature transcript near the binding site of the first recognition agent to an RNA/DNA hybrid and tagmentation of the RNA/DNA hybrid for use in preparing sequencing libraries of the RNA/DNA hybrid.
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
11.
CHIMERIC TRANSMEMBRANE POLYPEPTIDES COMPRISING A TGF BETA RECEPTOR EXTRACELLULAR DOMAIN, A TRANSMEMBRANE DOMAIN AND AN INTERLEUKIN RECEPTOR 2 INTRACELLULAR SIGNALLING DOMAIN AND ITS USE IN THERAPY
The present disclosure provides fusion proteins with novel signaling properties. Disclosed embodiments include fusion proteins that comprise an extracellular component that is capable of binding to a TGFβ polypeptide, a transmembrane component, and an intracellular component comprising a cytoplasmic domain from an IL-2Rβ or IL-2Rγ protein. Certain embodiments include a TGFβR intracellular overhang or overhang sequence extending from a TGFβR transmembrane domain, N-terminal to the IL-2R cytoplasmic domain. In response to TGFβ, the fusion proteins can initiate an IL-2 signal in a host cell, promoting, for example, proliferation of the host cells. Recombinant host cells expressing the fusion proteins, and an optional antigen-binding protein such as a TCR or a CAR, are provided. Also provided are polynucleotides encoding the fusion proteins, and vectors that comprise the polynucleotides. Also provided are compositions and methods comprising the same.
C07K 14/71 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des facteurs de croissanceRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des régulateurs de croissance
A61K 38/00 - Préparations médicinales contenant des peptides
C07K 14/715 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des cytokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des lymphokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des interférons
12.
MACHINE LEARNING MODEL FOR RAPIDLY PREDICTING CELL SEGMENTATION OF SPATIAL TRANSCRIPTOMIC CELL DATA
Biological landmark segmentation may comprise disambiguating which spatial transcriptomics data is associated with background noise and/or partitioning distinct biological landmark types, biological landmarks, and/or biological landmark features. An iterative process may be used to determine such a segmentation, the iterative process comprising modeling gene expression rates according to a current state of the segmentation; randomly altering a current state of the segmentation; determining an updated model of the gene expression rate based on the alteration; and determining to accept or reject the alteration based on a likelihood determined based on the updated model.
Engineered nanoparticles for genetic therapies in human blood cells are described and can be used to safely and efficiently treat a variety of genetic, infectious, and malignant diseases. Targeting of human stem cells is achieved through the binding of CD133, CD117, CD90, with linked targeting moieties that result in rapid internalization of the engineered nanoparticles following binding.
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
Anti-CD90 antibodies, binding fragments, and uses thereof are described. The provided antibodies and binding fragments can be used to isolate CD90 cells or to target such cells ex vivo or in vivo for a research, a diagnostic, or a therapeutic purpose. Anti-CD90 antibodies and binding fragments thereof can also be used in engineered formats to create antibody conjugates or within a recombinant protein to pseudotype viral vectors.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
A61K 51/10 - Anticorps ou immunoglobulinesLeurs fragments
A61K 51/12 - Préparations contenant des substances radioactives utilisées pour la thérapie ou pour l'examen in vivo caractérisées par un aspect physique particulier, p. ex. émulsion, microcapsules, liposomes
C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
in vivoin vivo recruitment, activation, and reprogramming of immune cells are described. Before implantation, the implants include columnar pores, chemoattractants, immune cell activating factors, and reprogramming factors.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
The present invention relates to methods and compositions for providing hematopoietic function to human patients in need thereof, by selecting a pool of expanded human cord blood stem/progenitor cell samples for administration to the patient, wherein the samples in the pool collectively do not mismatch the patient at more than 2 of the HLA antigens or alleles typed in the patient; and administering the selected pool of expanded human cord blood stem/progenitor cell samples to the patient. Methods for obtaining the pools of expanded human cord blood stem/progenitor cell samples, banks of frozen pools of expanded human umbilical cord blood stem/progenitor cell samples, and methods for producing such banks are also provided herein.
A61K 35/51 - Cordon ombilicalSang de cordon ombilicalCellules souches ombilicales
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
The invention generally relates to methods for identifying and using anticancer therapeutic agents and, more particularly, to methods for identifying and using inhibitors of genes for inhibiting the growth and/or proliferation of MYC-driven tumor cells relative to normal cells.
The present disclosure relates, in part, to the discovery that CD4+ T cells characterized by certain markers are over-represented in solid tumors. Markers include, for example, CD200, CXCL13, and PD-1, as well as combinations of these, and other markers. The markers can identify CD4+ T cells having certain phenotypes. Identifying such cells enables a variety of therapeutic and prognostic applications. Such CD4+ T cells will typically include those specific for a tumor neoantigen or antigen, and may be enriched for and/or expanded and used in a T cell therapy. TCRs from such CD4+ T cells may be used in therapy (e.g., comprising T cells recombinantly expressing such a TCR or an engineered TCR or binding domain derived therefrom). The relative presence or absence of such CD4+ T cells in a tumor sample can provide information regarding the immune state of the subject and the likely prognosis of disease.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
19.
DNA METHYLATION BIOMARKERS FOR DETECTION OF HIGH-GRADE DYSPLASIA AND ESOPHAGEAL OR JUNCTIONAL ADENOCARCINOMA
Methods and kits to distinguish normal or Barrett's esophageal samples from high grade dysplasia (HGD), esophageal adenocarcinoma (EAC), or junctional adenocarcinoma (JCA) samples are described. The methods and kits utilize the methylation status of epigenetic markers, such as cg6522, POU3F1, YPEL3, and/or MAFB.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
20.
IMMUNIZATION SCHEDULES TO ELICIT BROADLY-NEUTRALIZING ANTIBODIES AGAINST HUMAN IMMMUNODEFICIENCY VIRUS (HIV)
Immunization schedules to elicit the production of antibodies against the human immunodeficiency virus (HIV), including Tier 2 HIV, are described. The strategies include immunization utilizing engineered and multimerized HIV envelope glycoproteins and SOSIP trimers. When B cells effectively mature against the HIV virus, subjects can be protected against infection of HIV.
A61K 39/21 - Retroviridae, p. ex. virus de l'anémie infectieuse équine
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61P 31/18 - Antiviraux pour le traitement des virus ARN du HIV
Provided are adoptive cell therapy methods involving the administration of doses of cells for treating B cell malignancies. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the methods are for treating subjects with chronic lymphocytic leukemia (CLL). In some embodiments, the methods are for treating subjects with non-Hodgkin lymphoma (NHL). In some embodiments, the methods involve prior administration of a lymphodepleting therapy, such as prior administration of fludaribine and/or another lymphodepleting chemotherapeutic agent, for example cyclophosphamide. In some embodiments, features of the methods include an increase in complete remission, overall survival and/or progression free survival of subjects treated in accord with the provided methods.
A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
C07K 14/71 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des facteurs de croissanceRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des régulateurs de croissance
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
Described herein are compositions and methods for selective depletion of target molecules using a recyclable CDP-receptor-binding mediated complex to elicit endocytosis and cellular degradation of the target. Exemplary compositions containing a peptide, such as a CDP peptide, that bind a transferrin receptor can be linked to a peptide that binds a target molecule. Such compositions can be used to selectively recruit the target molecule to endosomes via transferrin receptor-mediated endocytosis of the composition and the bound target molecule. Once inside the endosome, the acidic pH can lead to release of the target molecule from the composition due to pH-dependent binding of the composition for the target molecule, and the transferrin receptor portion is recycled back to the cell surface for “reloading”. The target molecule can then be trafficked into lysosomes wherein it is degraded.
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
C07K 14/00 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
23.
COMPOSITIONS AND METHODS TO MODIFY CELLS FOR THERAPEUTIC OBJECTIVES
The present disclosure provides compositions and methods that rapidly and selectively modify cells of the immune system to achieve therapeutic objectives. The methods can be practiced in vivo and any cell type that expresses a known marker can be targeted for a therapeutic objective.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
C12N 15/88 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p. ex. co-transformation utilisant la micro-encapsulation, p. ex. utilisant des vésicules liposomiques
24.
BINDING PROTEINS SPECIFIC FOR RAS NEOANTIGENS AND USES THEREOF
The present disclosure provides compositions and methods for targeting a Ras antigen to, for example, treat or prevent cancer. Disclosed embodiments include binding proteins, such as T cell receptors bind to a Ras antigen:HLA complex.
The present disclosure provides compositions and methods for targeting a Ras antigen to, for example, treat or prevent cancer. Disclosed embodiments include binding proteins, such as T cell receptors bind to a Ras antigen:HLA complex.
Disclosed binding proteins are highly sensitive to antigen, capable of inducing activation of host T cells at low concentrations of peptide antigen. In certain embodiments, binding proteins of the present disclosure are non-alloreactive against, are substantially non-alloreactive against, and/or have a low risk of alloreactivity against (i) amino acid sequences from the human proteome and/or (ii) against human HLA alleles. Polynucleotides encoding such binding protein can introduced into a host cell, such as a T cell, and the cell can be used in immunotherapy for treating various cancers.
A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
C07K 16/32 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des produits de traduction des oncogènes
C07K 16/40 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre des enzymes
25.
HUMAN T CELL RECEPTOR PAIRS REACTIVE WITH HLA-A*02:01 RESTRICTED HUMAN PROSTATIC ACID PHOSPHATASE (PAP) EPITOPES
Aspects of the present disclosure relate to methods and compositions related to related to the preparation of immune cells, including engineered T cells having T cell receptors that target human prostatic acid phosphatase (PAP) and are useful in prostate cancer therapy.
A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
26.
GAS-BUBBLE BASED DEGRADING LIQUID FOAMS TO DELIVER NUCLEIC ACIDS
Gas-bubble based degrading liquid foams to deliver nucleic acids are disclosed. The nucleic acids can be delivered for a variety of research, diagnostic, and therapeutic uses, such as in situ CAR T and stem cell engineering. The foams can also be used for administration of therapeutic nucleic acids to anatomical sites, such as cancer sites, through direct application at the site or through the use of edible or drinkable foams in the case of esophageal cancers, the use of rectally applied foams to treat rectal or colorectal cancer, or the use of intraperitoneally injected foam to treat widespread ovarian cancer. The nucleic acids can be delivered in a vector, such as a lipid nanoparticle or a viral vector.
Systems and methods for modeling highly complex biological relations in machine-learned models, such as neural networks (e.g., such as deep neural networks (DNNs)), to predict biological outcomes and elucidate underlying mechanisms are described. The systems and methods utilize recursive feature elimination and scoring and can be utilized to prioritize particular compounds or treatments for clinical development and direct new avenues of research and development based on elucidated mechanisms.
G16B 5/00 - TIC spécialement adaptées à la modélisation ou aux simulations dans la biologie des systèmes, p. ex. réseaux de régulation génétique, réseaux d’interaction entre protéines ou réseaux métaboliques
G16B 15/30 - Ciblage de médicament à l’aide de données structurellesPrévision d’amarrage ou de liaison moléculaire
G16B 25/10 - Profilage de l’expression de gènes ou de protéinesEstimation ou normalisation de ratio d’expression
G16H 50/50 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour la simulation ou la modélisation des troubles médicaux
28.
BINDING PROTEINS AND ENGINEERED CELLS SPECIFIC FOR NEOANTIGENS AND USES THEREOF
The present disclosure provides compositions and methods for targeting a neoantigen to, for example, treat or prevent cancer. Disclosed embodiments include binding proteins, such as T cell receptors bind to a neoantigen:HLA complex. Disclosed binding proteins are highly sensitive to antigen, capable of inducing activation of host T cells at low concentrations of peptide antigen. In certain embodiments, binding proteins of the present disclosure are non-alloreactive against, are substantially non-alloreactive against, and/or have a low risk of alloreactivity against (i) amino acid sequences from the human proteome and/or (ii) against human HLA alleles. Polynucleotides encoding such binding protein can introduced into a host cell, such as a T cell, and the cell can be used in immunotherapy for treating various cancers.
A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
e.g.e.g. e.g. T) cell signaling properties. Certain embodiments provide a chTCR that binds to a human CD22 (e.g., in an extracellular domain thereof). In certain further embodiments, the chTCR further comprises a binding domain that binds a human CD19. In other embodiments, the present disclosure provides chTCRs that bind human GPRC5D and human BCMA. In other embodiments, the present disclosure provides chTCRs that bind human SLAMF7 and human BCMA. Also provided are polynucleotides encoding the chTCRs, and vectors that comprise the polynucleotides. Also provided are host cells, such as T cells, that encode or express the chTCR. Also provided are compositions and methods for using the same the same.
A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie
A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
Chimeric antigen receptor (CAR) with a binding domain that binds STEAP1 are disclosed. The CAR disclosed herein can be used in the treatment of prostate cancer, the Ewing family of tumors (EFT), bladder cancer, ovarian cancer, and rhabdomyosarcoma. The CAR disclosed herein can bind and elicit cytotoxic effects even in low antigen density conditions.
A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
In certain examples, computer-implemented methods involve assessing patient diagnosis utilizing RNA expression profiles. As may be implemented in accordance with one or more aspects characterized herein, a landscape of RNA expression profiles may be generated from a plurality of patients having a set of common medical attributes. An RNA expression profile is obtained for a target patient having the medical attributes, and a plurality of nearest neighbor RNA expression profiles are identified from the landscape of RNA expression profiles, based on the target patient's RNA expression profile. A diagnosis for the target patient is provided based on known characteristics of the plurality of patients corresponding to the identified nearest neighbor RNA expression profiles.
G16B 25/10 - Profilage de l’expression de gènes ou de protéinesEstimation ou normalisation de ratio d’expression
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
The present disclosure includes MGMT modifications that cause MGMT resistance to MGMT inhibitors. The present disclosure also includes in vivo, in vitro, and ex vivo modification of MGMT-encoding nucleic acids to encode and express an MGMT variant that is resistant to MGMT inhibitors. Inhibitor-resistant MGMT modifications and modification of an MGMT-encoding nucleic can occur or be used in conjunction with a therapeutic modification, e.g., in a single cell. Expression of inhibitor-resistant MGMT can selectively protect modified cells from a selection regimen, such as a selection regimen including an MGMT inhibitor and an alkylating agent. Accordingly, in vivo, in vitro, and ex vivo modification of MGMT-encoding nucleic acids can be used in gene therapy to select for modified cells.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
Seattle Children’s Hospital d/b/a Seattle Children (USA)
Fred Hutchinson Cancer Center (USA)
Inventeur(s)
Hahn, Sihoun
Jung, Sunhee
Whiteaker, Jeffrey
Torgerson, Troy
Paulovich, Amanda
Collins, Christopher
Dayuha, Remwilyn
Abrégé
Newborn screening for primary immunodeficiencies, cystinosis, and Wilson disease is described. The newborn screening can detect these disorders from dried blood spots already routinely collected at the time of birth. Early detection of these disorders will greatly improve patient outcome as each of them can be fatal once symptoms emerge.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
35.
METHODS AND COMPOSITIONS FOR IMPROVING T CELL IMMUNOTHERAPY
e.g.e.g., CD8+ T cells, CD4+ T cells, or both) with (1) TGFβ (or a functional analog, mimic, or fragment thereof) and (2) an inhibitor of LSD1 activity and/or expression. The present disclosure also provides methods comprising increasing expression or activity of GPX4 in T cells, which, as taught herein, can improve T cell functionalities.
ex vivoin vivoin vivo for a research, a diagnostic, or a therapeutic purpose. Anti-CD90 antibodies and binding fragments thereof can also be used in engineered formats to create multi-domain binding molecules, antibody conjugates, recombinant receptors, or within a recombinant protein to pseudotype viral vectors.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
The present disclosure provides compositions and methods for targeting a Ras antigen to, for example, treat or prevent cancer. Disclosed embodiments include binding proteins, such as a T cell receptor or a chimeric antigen receptor, that bind to a Ras antigen:HLA complex. Polynucleotides encoding such binding protein can introduced into a host cell, such as a T cell, and the cell can be used in immunotherapy for treating various cancers. Also provided are immunogenic polypeptides that can be useful to, for example, induce an immune response against a mutated Ras or to identify a binding protein that binds to a Ras antigen.
The present technology provides engineered proteins bispecific to CD3 and NKG2DL, and method of using the engineered proteins for modulating lymphocyte function and treating a variety of diseases, including age-associated diseases and cancer.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
Described herein are immunomodulatory fusion proteins containing an extracellular binding domain and an intracellular signaling domain, wherein binding of a target can generate a modulatory signal in a host cell, such as a T cell. Some immunomodulatory fusion proteins as described comprise a SIRPα extracellular component and hydrophobic and intracellular components comprising transmembrane and/or signaling domains of a CD28, respectively. Such fusion proteins are capable of delivering a positive or costimulatory signal in response to a binding event that in a natural setting would result in an inhibitory signal. Uses of immune cells expressing such immunomodulatory fusion proteins to treat certain diseases, such as cancer or infectious disease, are also described.
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
A61K 38/00 - Préparations médicinales contenant des peptides
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
DNA hypomethylation as a predictive marker for cancer therapy is described. The susceptibility of hypomethylated cancers to particular treatments, for example to AKT inhibitors and anthracyclines is described. The described susceptibilities can be used to direct enrollment of subjects into appropriate clinical trials and to guide treatment selection and administration based on global DNA methylation level.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
41.
COMBINATION OF A CELL THERAPY AND A GAMMA SECRETASE INHIBITOR
Provided herein are combination therapies involving administration of an immunotherapy involving a cell therapy, such as a T cell therapy, and an inhibitor of gamma secretase. Also provided are methods for engineering, preparing, and producing the cells, compositions containing the cells and/or gamma secretase inhibitor, and kits and devices containing and for using, producing and administering the cells and/or gamma secretase inhibitor, such as in accord with the provided combination therapy methods.
A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
C07K 14/715 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des cytokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des lymphokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des interférons
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
42.
METHOD FOR ANALYZING THE ABILITY OF TARGET NUCLEIC ACID SEQUENCES TO IMPACT GENE EXPRESSION
A method for analyzing an ability of target nucleic acid sequences to impact gene expression is described. In an embodiment, the method includes cloning the target nucleic acid sequences and associated barcode nucleic acid sequences into a plurality of plasmids, sequencing the plasmids to provide long-read sequencing information based on a target nucleic acid sequence of the target nucleic acid sequences and an associated barcode nucleic acid sequence, associating the target nucleic acid sequence with the associated barcode nucleic acid sequence based on the long-read sequencing information, transducing the plurality of plasmids into a plurality of cells, extracting DNA, total mRNA, and polysome-bound mRNA from the cells, sequencing the barcode nucleic acid sequences in the extracted DNA, total mRNA, and polysome-bound mRNA to provide short-read sequencing information, and analyzing the target nucleic acid sequences by comparing the long-read sequencing information and the short-read sequencing information.
Provided herein are methods and compositions for overcoming resistance to and/or augmenting efficacy of Prostate specific membrane antigen (PSMA)-directed therapies in a subject. In some embodiments, the method comprises administering to the subject in need thereof an effective amount of at least one agent capable of modulating the expression of PSMA. The disclosure also is directed to a method for sensitizing a cancer to a PSMA-targeted therapeutic agent and/or a PSMA-targeted theranostic agent in a subject in need thereof. Also provided are methods and compositions for treating prostate cancer in a subject in need thereof.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
44.
COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES WITH ISOCITRATE DEHYDROGENASE 1/2 MUTATIONS
Compositions and methods for treatment of conditions associated with IDH1/2 mutation(s) are disclosed. The compositions and methods include administering an SRC inhibitor and a p70 S6 kinase/AKT (S6K/AKT) inhibitor. Examples of conditions associated with IDH1/2 mutation(s) include intrahepatic cholangiocarcinoma (ICC), oligodendrogliomas, astrocytomas, glioblastomas, leukemias, adenocarcinoma, gliomas, melanomas, oligoastrocytomas, invasive breast carcinoma, invasive ductal carcinoma, and myelodysplastic syndromes.
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 31/517 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. quinazoline, périmidine
Methods and compositions for modulating the myeloid arm of the immune system are described. The methods and compositions modulate the myeloid arm of the immune system by stimulating or inhibiting Sema4 and/or a PlexinD1 receptor. Stimulating Sema4 and/or a PlexinD1 receptor down-regulates or dampens the myeloid arm of the immune system while inhibiting Sema4 and/or a PlexinD1 receptor up-regulates or heightens the myeloid arm of the immune system. The ability to modulate the myeloid arm of the immune system provides many advances such as reducing immune-responsiveness to various forms of stress and enhancing immune responsiveness to physiological challenges.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
46.
COMPOSITIONS AND METHODS FOR CELLULAR IMMUNOTHERAPY
The present application concerns chimeric co-receptor constructs, especially CD8-alpha (CD8α), CD8-beta (CD8β) or CD3-zeta (CD3ζ) chains comprising an intracellular co-stimulatory domain. In particular, the application discloses fusion proteins comprising the extracellular domain of CD8-alpha (CD8α), CD8-beta (CD8β) or CD3-zeta (CD3ζ) chains, a transmembrane domain, and an intracellular co-stimulatory domain, especially that of CD28, 4-1BB (CD137), and others. These engineered polypeptides and expression constructs are useful to confer to, or improve, a desired activity or function of a host cell, such as an immune cell that targets a diseased or pathogenic cell (e.g. a cancer cell). These polypeptides may improve cellular function, such as in the context of adoptive cell therapy, for example, comprising CD4+ T cells expressing an antigen-specific receptor.
Siglec-8 antibodies and uses thereof are described. The Siglec-8 antibodies can be fully human and can be used for a variety of purposes, including in the research, diagnosis, and treatment of eosinophil and mast cell related disorders, such as asthma, rhinitis, dermatitis, eosinophilic gastrointestinal disorders, eosinophilic pneumonia, anaphylaxis, urticaria, eosinophilic cellulitis and fasciitis, Churg-Strauss syndrome, hematologic malignancies involving eosinophils or mast cells, and mastocytosis.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
Anti-CD33 antibodies are described. The anti-CD33 antibodies can bind within the V-set Ig-like domain or the C2-set Ig-like domain of CD33. Epitopes on the C2-set Ig-like domain can provide a “pan-binding” site, to which the cognate antibody will bind regardless of whether the CD33 molecule also contains the V-set domain (as in, for example, CD33FL) or not (as in, for example, CD33ΔE2). Alternative epitopes on the C2-set Ig-like domain are accessible for binding if the V-set domain is absent (e.g., as in CD33ΔE2). Antibodies that bind an epitope on the C2-set Ig-like domain (whether they exhibit pan or V-set absent binding) are directed at novel therapeutic targets and can increase therapeutic efficacy against CD33-related disorders. Also described are molecules comprising a binding-competent domain from at least one described anti-CD33 antibody, including scFvs, bi-specific antibody molecules, chimeric antigen receptors, and immunoconjugates. Methods of use are also provided.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie
49.
SYSTEMS AND METHODS FOR MOBILE-ENABLED TARGETED NANOPORE SEQUENCING WITH MOBILE-ENABLED REAL-TIME FUSION DETECTION
In some embodiments, a computer-implemented method of processing nanopore signals to detect one or more predetermined features of a feature library in a sample used to generate the nanopore signals is provided. A computing device receives an electrical signal record generated by a flow cell, and breaks the electrical signal record into a plurality of chunks. The computing device generates partial base pair information by basecalling electrical signals of a first chunk of the plurality of chunks, and generates an alignment for the partial base pair information. In response to determining that the alignment corresponds to at least one predetermined feature in the feature library, the computing device executes a feature detection pipeline on the electrical signal record. In response to determining that the alignment does not correspond to at least one predetermined feature in the feature library, the computing device discards the electrical signal record.
Targeted therapeutics for the treatment of cancers expressing FOLR1, MEGF10, HPSE2, KLRF2, PCDH19, and/or FRAS1 are described. The targeted therapeutics can include a chimeric antigen receptor (CAR) expressed by an immune cell or an antibody-targeted therapeutic. The targeted therapeutics can be used to treat a variety of cancers including solid tumors and blood cancers, such as CBFA2T3-GLIS2 acute myeloid leukemia (C/G AML).
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
A61K 51/10 - Anticorps ou immunoglobulinesLeurs fragments
A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/40 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre des enzymes
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
52.
TREATING ALPHAHERPESVIRUS INFECTIONS USING GENE DRIVE TECHNOLOGY
Provided are genetically modified viruses and methods of suppressing and/or preventing infection or a recurrence of an infection caused by a wild-type alphaherpesvirus. In certain embodiments, the methods involve co-infecting a cell comprising the wild-type alphaherpesvirus with at least one modified alphaherpesvirus containing a gene drive construct; wherein the modified alphaherpesvirus is effective in genetically modifying/altering the wild-type alphaherpesvirus by integrating/inserting the gene drive construct into the genome of the wild-type virus at a target site, and wherein the integration/insertion of the gene drive construct disrupts at least one viral gene at the target site in the genome of the wild-type virus. In some embodiments, the cell comprises a cell of a latent reservoir. In some embodiments, the wild-type alphaherpesvirus and the modified alphaherpesvirus are selected from HSV-1 and HSV-2. In certain embodiments, the at least one viral gene is a gene involved in anterograde transport of the virus.
The present disclosure provides compositions and methods for targeting SOX2 antigen to, for example, treat or manage cancer. Provided compositions include binding proteins that are capable of binding to a SOX2 antigen:HLA complex. Also provided are polynucleotides and transgene constructs encoding binding proteins, such as a T cell receptor or a chimeric antigen receptor, that specifically bind to a SOX2 antigen. Such polynucleotides and transgene constructs can be introduced into an immune cell, such as a T cell, and used in immunotherapy in a subject having or at risk for a cancer associated with SOX2 expression or activity. The present disclosure also provides immunogenic compositions comprising SOX2 antigens, and related uses.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
Single-domain antibodies that bind receptor tyrosine kinase (ROR1) are described. The single-domain antibodies can be used for multiple purposes including in research, imaging, diagnosis, and treatment of ROR1-related conditions. The disclosed single-domain antibodies can be used as anti-cancer therapeutics such as antibody-drug conjugates, multi-domain binding molecules, or recombinant receptors or can be used as cancer imaging/diagnostic agents.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
G01N 33/60 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées faisant intervenir des substances marquées radioactives
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
09 - Appareils et instruments scientifiques et électriques
16 - Papier, carton et produits en ces matières
35 - Publicité; Affaires commerciales
36 - Services financiers, assurances et affaires immobilières
41 - Éducation, divertissements, activités sportives et culturelles
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
45 - Services juridiques; services de sécurité; services personnels pour individus
Produits et services
Reagents and monoclonal antibodies for in vitro scientific
or research use. Diagnostic reagents and monoclonal antibodies for medical
use. Downloadable electronic publications in the nature of
newsletters, pamphlets, brochures, magazines, instruction
sheets, and manuals in the fields of research, prevention,
detection, treatment, and cure of cancer, HIV/AIDS, other
diseases, and related medical and public health problems. Printed publications, namely, newsletters, pamphlets,
brochures, magazines, instruction sheets, and manuals in the
fields of research, prevention, detection, treatment, and
cure of cancer, HIV/AIDS, other diseases, and related
medical and public health problems. Promoting public awareness about cancer; promoting public
awareness about research, prevention, diagnosis, treatment,
and cure of cancer, HIV/AIDS, public health problems, and
other diseases; providing information regarding promotional
events for public awareness of cancer via a website;
providing information regarding promotional events for
public awareness of research, prevention, diagnosis,
treatment, and cure of cancer, HIV/AIDS, public health
problems, and other diseases via a website; providing
medical referrals, namely, business administrative services
for medical referrals; retail pharmacy services. Charitable fund raising in the area of research, prevention,
detection, treatment, and cure of cancer and related medical
and public health problems. Educational services, namely, developing and disseminating
educational materials and programs of others to healthcare
providers and patients in the fields of prevention,
diagnosis, treatment, and cure of cancer, HIV/AIDS, public
health problems, and other diseases; educational services,
namely, providing classes, seminars, workshops, and
conferences in the fields of prevention, diagnosis,
treatment, and cure of cancer, HIV/AIDS, public health
problems, and other diseases, and distribution of
educational materials in connection therewith; providing
non-downloadable articles in the fields of prevention,
diagnosis, treatment, and cure of cancer, HIV/AIDS, other
diseases, and public health problems via a website;
providing on-line non-downloadable publications in the
nature of newsletters, pamphlets, brochures, magazines,
instruction sheets, and manuals in the fields of research,
prevention, detection, treatment, and cure of cancer. Consulting related to medical research in the fields of
cancer and related medical conditions; medical and
scientific research in the fields of cancer treatment and
diagnosis; scientific research for medical purposes in the
fields of cancer, infectious diseases and related medical
and public health problems; medical laboratory services. Medical consultations, namely, consultation services in the
fields of prevention, diagnosis, treatment, and cure of
cancer, HIV/AIDS, other diseases, and public health
problems; medical services; medical consulting services,
namely, providing medical second opinions, and prevention,
diagnostic, and treatment protocols for cancer and related
medical conditions; medical consulting services, namely,
consulting on the treatment of cancer and other diseases,
disease management, disease prevention, early detection of
disease, performing standardized diagnosis of disease,
staging and treatment of disease, medical care and medical
care assessment, and patient care management; medical
services, namely, medical counseling, diagnostic testing,
and treatment services for patients with cancer and related
medical conditions; medical consulting services in the area
of clinical programs for bone marrow and stem cell
transplants; medical services, namely, the treatment of
cancer and other diseases, disease management, disease
prevention, early detection of disease, performing
standardized diagnosis of disease, staging and treatment of
disease, medical care and medical care assessment, and
counseling; medical services, namely, patient networking in
the nature of providing a website via a global computer
network featuring information in the fields of health,
cancer treatment, cancer recovery and survival; medical and
health clinic services, namely, providing clinical care for
patients with cancer and related medical conditions,
HIV/AIDS, and other diseases; outpatient medical services;
home health care services; medical diagnosis services,
namely, performing diagnosis of cancer, HIV/AIDS and related
medical and public health problems; medical screening
services for cancer, HIV/AIDS, and related medical and
public health problems; medical imaging services; medical
analysis services for diagnostic and treatment purposes
provided by medical laboratories; provision of health care
and medical services by health care professionals via the
Internet or telecommunication networks; medical services,
namely, medical and psychological counseling services for
patients and families of patients; health care services,
namely, disease prevention in the nature of medical
screenings, clinical diagnosis and wellness programs;
dietary and nutritional guidance services; providing
information in the fields of prevention, diagnosis,
treatment, the cure of cancer, HIV/AIDS, public health
problems, and other disease via a website. Providing personal support services for patients and
families of patients with cancer, namely, emotional
counseling and emotional support; providing patient advocate
services in the fields of prevention, diagnosis, treatment
and cure of cancer, HIV/AIDS, public health problems, and
other diseases; providing a website via a global computer
network featuring supportive personal stories on the
subjects of health, cancer, cancer recovery and survival;
patient networking in the nature of online social networking
services in the field of medical care; community outreach
and patient counseling regarding disease prevention and
wellness programs, namely, organizing and conducting
in-person and online support groups in the field of cancer
for patients and families of patients with cancer.
56.
COMPOSITIONS AND METHODS FOR ACCURATELY IDENTIFYING MUTATIONS
The present disclosure provides compositions and methods for accurately detecting mutations by uniquely tagging double stranded nucleic acid molecules with dual cyphers such that sequence data obtained from a sense strand can be linked to sequence data obtained from an anti-sense strand when sequenced, for example, by massively parallel sequencing methods.
Alpha(v) beta (8) integrin (αvβ8)-selective binding polypeptides and their use for treating or inhibiting cancer or tissue fibrosis are provided, where the polypeptides have an ammo acid sequence at least 50% identical to the amino acid sequence selected from SEQ ID NO: 1-6, not including any amino acid insertions, wherein the polypeptide selectively binds to αvβ8, and wherein: (a) residues 10-12 relative to the reference sequence are RGD (b) residue 13 relative to the reference sequence is F, M, or L; (c) residue 16 relative to the reference sequence is Y or V; and (d) residue 40 relative to the reference sequence is D, E, or P.
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
Compositions and methods useful in preventing, reducing, delaying, diagnosing, and treating cancer and in studying the effects of cancer-associated microbes are described. The compositions and methods can be used to detect and study cancer-associated microbes and/or attenuate, modify, or utilize the effects of the cancer-associated microbes. Compositions and methods to modulate the effects of the cancer-associated microbes include the use of vaccines, inhibitors, genetic engineering, immunotherapy, cell therapy, and chemotherapeutic treatments.
C07K 14/195 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
59.
COMPOSITIONS AND METHODS FOR ACCURATELY IDENTIFYING MUTATIONS
The present disclosure provides compositions and methods for accurately detecting mutations by uniquely tagging double stranded nucleic acid molecules with dual cyphers such that sequence data obtained from a sense strand can be linked to sequence data obtained from an anti-sense strand when sequenced, for example, by massively parallel sequencing methods.
A system generates a visualization that represents progression of a cancer genome. To generate the visualization, the system obtains a genetic dataset derived from cancer cell samples of a patient and clinical data associated with the patient. A genomic data structure is generated to represent the genetic dataset, and clinical event data structures are generated to represent each of a plurality of clinical events based on the clinical data. The visualization includes interactive elements that are populated based on the genomic data structure and the clinical event data structures. When a user input associated with a first interactive element is detected, the system displays information associated with the first interactive element based on the genomic data structure or the clinical event data structures.
G16H 50/70 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour extraire des données médicales, p. ex. pour analyser les cas antérieurs d’autres patients
G06F 9/451 - Dispositions d’exécution pour interfaces utilisateur
G16H 10/60 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données spécifiques de patients, p. ex. pour des dossiers électroniques de patients
61.
COMPOSITIONS AND METHODS FOR ACCURATELY IDENTIFYING MUTATIONS
The present disclosure provides compositions and methods for accurately detecting mutations by uniquely tagging double stranded nucleic acid molecules with dual cyphers such that sequence data obtained from a sense strand can be linked to sequence data obtained from an anti-sense strand when sequenced, for example, by massively parallel sequencing methods.
Described herein are compositions and methods for reducing or eliminating latent herpes simplex virus type 2 (HSV-2) from an HSV-2-infected cell, or for reducing or eliminating latent HSV-2 reactivation in an HSV-2-infected cell, leading to a viable curative approach for latent HSV-2 infection. The composition comprises a plurality of viral vectors, wherein the viral vectors comprise a sequence encoding an HSV-2-specific meganuclease. The method comprises delivering to an HSV-2-infected cell a plurality of one or more viral vectors, wherein each of the one or more viral vectors includes a sequence encoding an HSV-2-specific meganuclease.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
in situ in situin situ methods for measuring transcription in a cell from a formalin-fixed paraffin-embedded (FFPE) sample. The methods can include steps of treating the FFPE sample to remove paraffin; permeabilizing the sample; contacting the sample with a first affinity reagent that specifically binds to a targeted chromatin protein or a protein involved in transcription regulation, wherein the first affinity reagent is coupled to a transposome comprising at least one transposase and a transposon; activating the at least one transposase under low ionic conditions, thereby cleaving and tagging chromatin DNA; excising the tagged DNA segment associated with the targeted chromatin protein or protein involved in transcription regulation; and determining the nucleotide sequence of the excised tagged DNA segment, thereby mapping the genomic location of the targeted protein on chromatin or transcriptional activity on chromatin.
G01N 33/567 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet utilisant un support spécifique ou des protéines réceptrices comme réactifs pour la formation de liaisons par ligand utilisant un extrait de tissu ou d'organe comme agent de liaison
METHODS FOR IDENTIFYING AND USING INHIBITORS OF CASEIN KINASE 1 EPSILON ISOFORM FOR INHIBITING THE GROWTH AND/OR PROLIFERATION OF MYC-DRIVEN TUMOR CELLS
In one aspect, the invention provides a method for inhibiting the growth and/or proliferation of a myc-driven tumor cell comprising the step of contacting the tumor cells with a CSNK1ε inhibitor. In another aspect, the invention provides a method of treating a subject suffering from a tumor comprising myc-driven tumor cells, comprising administering to the subject an amount of a composition comprising a CSNK1ε inhibitor effective to inhibit the growth and/or proliferation of the tumor cells.
The present application relates to neutralizing antibodies or antigen-binding fragments thereof against betacoronaviruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), to nucleic acid(s) encoding such neutralizing antibodies or antigen-binding fragments thereof, and to mixture and compositions comprising such antibodies, antigen-binding fragments or nucleic acids. Methods and uses of the antibodies, antigen-binding fragments thereof, nucleic acid(s) or compositions, including therapeutic, diagnostic, and preventative methods and uses for betacoronavirus infections and related diseases such as COVID-19, are also described.
Seattle Children's Hospital, dba Seattle Children's Research Institute (USA)
Inventeur(s)
Jensen, Michael C.
Riddell, Stanley R.
Hudecek, Michael
Abrégé
The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring CD8+ central memory T cells or combinations of central memory T cells with CD4+ T cells that are genetically modified to express a chimeric receptor. In embodiments the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a ligand binding domain, a polynucleotide comprising a customized spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain. It has been surprisingly found that the length of the spacer region can affects the ability of chimeric receptor modified T cells to recognize target cells in vitro and affects in vivo efficacy of the chimeric receptor modified T cells. Pharmaceutical formulations produced by the method, and methods of using the same, are also described.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
C07K 14/715 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des cytokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des lymphokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des interférons
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/32 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des produits de traduction des oncogènes
C07K 16/40 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre des enzymes
Described herein are compositions and methods for reducing or eliminating latent herpes simplex virus type 2 (HSV-2) from an HSV-2-infected cell, or for reducing or eliminating latent HSV-2 reactivation in an HSV-2-infected cell, leading to a viable curative approach for latent HSV-2 infection. The composition comprises a plurality of viral vectors, wherein the viral vectors comprise a sequence encoding an HSV-2-specific meganuclease. The method comprises delivering to an HSV-2-infected cell a plurality of one or more viral vectors, wherein each of the one or more viral vectors includes a sequence encoding an HSV-2-specific meganuclease.
In some aspects, the present disclosure provides a computer-implemented method of predicting efficacies of drugs in a diversity drug set. In general, a computing system receives test results for drugs in a principal drug set for samples of a subject. The computing system trains at least one machine learning model to generate functional predicted results of drugs in the diversity drug set based on the test results for drugs in the principal drug set, and predicts functional predicted results of drugs in the diversity drug set by providing features of the drugs in the diversity drug set as input to the at least one machine learning model.
G16B 15/30 - Ciblage de médicament à l’aide de données structurellesPrévision d’amarrage ou de liaison moléculaire
G16C 20/70 - Apprentissage automatique, exploration de données ou chimiométrie
G16H 20/10 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p. ex. pour s’assurer de l’administration correcte aux patients
G16H 50/50 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour la simulation ou la modélisation des troubles médicaux
Provided herein are biomarkers, methods of diagnosing, methods of treatment, methods of monitoring treatment, and methods of selecting treatment in a subject suspected of, or suffering from, Pancreatic cancer. In some embodiments, the methods disclosed herein comprise determining expression levels of at least one biomarker in one or more biological sample obtained from the subject, and comparing the expression levels of the at least one biomarker in the one or more biological sample obtained from the subject with an expression level of the at least one biomarker in a reference/control sample. In some embodiments, the at least one biomarker comprises High mobility Group A2 (HMGA2). In some embodiments, the pancreatic cancer is Pancreatic Ductal Adenocarcinoma (PDA). Also provided herein are reagents, compositions, and kits for the detection, diagnosis, and prognosis of pancreatic cancer.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
A61K 31/337 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à quatre chaînons, p. ex. taxol
A61K 31/7068 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p. ex. cytidine, acide cytidylique
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
Genetic constructs expressing a pro-inflammatory cytokine and a recombinant receptor, such as a chimeric antigen receptor (CAR), with a binding domain that binds STEAP1 are disclosed. The genetic constructs disclosed herein can be used in the treatment of prostate cancer, the Ewing family of tumors (EFT), bladder cancer, ovarian cancer, and rhabdomyosarcoma. The genetic constructs disclosed herein provide enhanced recombinant receptor cytotoxicity, the ability to bind and elicit cytotoxic effects even in low antigen density conditions, and enhanced interferon-gamma signaling which remodels the tumor microenvironment, further improving endogenous antitumor immunity.
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
C07K 16/32 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des produits de traduction des oncogènes
Embodiments of the present disclosure provide methods for treating a subject with cancer, wherein the cancer is characterized by a change-of-function or loss of-function mutation in a recurrently mutated RNA splicing factor gene. In some embodiments, the method can comprise administering to a subject a therapeutically effective amount of a composition that inhibits expression of a trans-acting splicing factor and/or inhibits expression of a cis-acting splicing factor, wherein a cancer-causing error triggered by the change-of-function or loss-of-function mutation in a recurrently mutated RNA splicing factor gene is partially or fully rescued by inhibiting expression of the trans-acting splicing factor and/or inhibiting expression of the cis-acting splicing factor.
The present disclosure relates to anti-ROR1 binding proteins, including those that bind to a ROR1 or portion thereof such as an intracellular C terminal portion of a ROR1 protein, and the use of such binding proteins in immunohistochemical and diagnostic methods. Related kits and methods of using the binding proteins are also provided, as are methods of treatment of subjects having diseases or conditions determined to be candidates for such treatments by the binding proteins or methods of this disclosure.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
The present disclosure provides therapeutic treatments for a disease such as a cancer or a tumor, including methods for treating SWI/SNF chromatin remodeling complex mutant tumors or cancers in a subject in need thereof. In an embodiment, the method comprises administering to the subject a therapeutically effective amount of at least one agent effective in suppressing or inhibiting mRNA translation. In an embodiment, the cancer or tumor is an ARID1A mutant and/or an ARID1A-deficient cancer or tumor. In some embodiments, the therapeutic treatments disclosed include methods of treating ARID1A mutant and/or ARID1A-deficient cancer in a subject comprising the step of administering a therapeutically effective amount of an agent effective in inhibiting mRNA translation elongation. In some embodiments, the agent effective in inhibiting mRNA translation elongation is an agent effective in suppressing or inhibiting eukaryotic elongation factor 2 (eEF2).
Binding domains that bind the four dengue virus (DENV) serotypes are described herein. In some cases, the binding domains also bind Zika virus (ZIKV). The binding domains can be used to neutralize DENV or DENV and ZIKV.
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (USA)
Inventeur(s)
Haffner, Michael
Low, Jin-Yih
Wasmuth, Elizabeth
Mittal, Chitvan
Abrégé
In some embodiments, the present disclosure provides steroid hormone receptor ligand binding peptides comprising at least 6 contiguous amino acid residues found within the carboxy terminal receptor binding domain of the PRAC1 protein. Methods for the use of the peptides and their derivatives, pharmaceutical compositions comprising the peptides and their derivatives in treating a steroid hormone driven cancer and inhibiting the interaction between the steroid hormone receptor, its co-factors, and its ligand are also provided. Additionally, provided herein is a method of overcoming resistance or restoring sensitivity to a therapy targeting the androgen receptor signaling axis in a subject suffering from a steroid hormone driven cancer.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/48 - Matériau biologique, p. ex. sang, urineHémocytomètres
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
C12Q 1/686 - Réaction en chaine par polymérase [PCR]
Embodiments of the present disclosure are directed to methods and compositions for reducing or eliminating latent HSV-1 reactivation in a cell. In some embodiments, the method comprises delivering to an HSV-1-infected cell one or more self-complementary adeno-associated viruses (scAAV) comprising one or more sequences encoding one or more HSV-1-specific meganucleases. In some embodiments, the composition comprises one or more self-complementary adeno-associated viruses (scAAV) comprising one or more sequences encoding one or more HSV-1-specific meganucleases.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
A61K 31/517 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. quinazoline, périmidine
A61K 31/5383 - 1,4-Oxazines, p. ex. morpholine condensées en ortho ou en péri avec des systèmes hétérocycliques
A61K 31/5517 - 1,4-Benzodiazépines, p. ex. diazépam condensées avec des cycles à cinq chaînons ayant l'azote comme hétéro-atome d'un cycle, p. ex. imidazobenzodiazépines, triazolam
A61K 38/00 - Préparations médicinales contenant des peptides
A61P 31/22 - Antiviraux pour le traitement des virus ADN des virus de l'herpès
Methods, compositions, computational methodologies, and kits for cost-effective and improved detection and characterization of leukemia mutations for treatment of leukemia. Leukemias frequently present with recurrent gene fusions, which can be drivers of disease pathophysiology. The disclosed approaches do not utilize amplification of polynucleotides, lowering energy requirements and current financial and socioeconomic barriers limiting access to diagnostics and treatments. The disclosed approaches facilitate identification of leukemia genomic variants and help stratify diseases by risk, facilitating improved therapy choices, including for cost-sensitive communities with limited access to biomedical testing services.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
The present technology provides chimeric antigen receptors (CARs) targeting programmed death protein 1 (PD-1), host cells (e.g., T cells) that contain and/or express the anti-PD-1 CARs, and methods of using the CAR T cells for treating a variety of diseases including HIV, HIV-associated conditions, cancer, and autoimmune diseases.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
Described herein are cystine-dense peptides capable of binding to PD-L1. Such peptides may function as PD-L1 inhibitors by binding to the PD-1-binding interface of PD-L1 and inhibiting interactions between PD-L1 and PD-1. Methods of using PD-L1-binding peptides to treat cancers, autoimmune diseases, or other conditions are also described herein. Such methods include delivering active agents complexed with a PD-L1-binding peptide to a PD-L1 positive cell or using a bispecific immune cell engager to recruit immune cells to PD-L1 positive cells. Also described herein are chimeric antigen receptors comprising PD-L1-binding peptides.
C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
80.
COMPOSITIONS AND METHODS TO PROGRAM THERAPEUTIC CELLS USING TARGETED NUCLEIC ACID NANOCARRIER
Compositions and methods that rapidly and selectively modify hematopoietic stem cells (or cells derived therefrom) to achieve therapeutic objectives by providing for transient expression of nucleic acids are described. The transient expression leads to permanent therapeutic changes in the modified cells, referred to herein as “hit and run” effects.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
C12N 15/88 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p. ex. co-transformation utilisant la micro-encapsulation, p. ex. utilisant des vésicules liposomiques
81.
TCRS SPECIFIC FOR MINOR HISTOCOMPATIBILITY (H) ANTIGEN HA-1 AND USES THEREOF
The present disclosure provides compositions and methods for targeting a minor histocompatibility (H) antigen (HA-1H) to, for example, prevent or manage relapse of a hematological malignancy after allogeneic hematopoietic stem cell transplantation (HCT). Also provided are transgene constructs encoding engineered binding proteins, such as a T cell receptor or a chimeric antigen receptor, optionally encoding additional components such as a co-receptor and/or safety switch. Such transgene constructs can be transduced into an immune cell, such as a T cell, and used as an immunotherapy in a subject having a hematological malignancy or at risk for recurrence of the hematological malignancy (e.g., leukemia, lymphoma, myeloma).
A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
C07K 14/71 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des facteurs de croissanceRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des régulateurs de croissance
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
The present disclosure provides compositions and methods for targeting a P53 antigen to, for example, treat or prevent cancer. Disclosed embodiments include binding proteins, such as T cell receptors bind to a P53 antigen:HLA complex. In some embodiments, a P53 antigen is a peptide comprising a R175H mutation, such as a peptide comprising or consisting of the amino acid sequence of SEQ ID NO:3. Disclosed binding proteins are in some embodiments highly sensitive to antigen and are capable of inducing activation of host T cells at low concentrations of peptide antigen. Polynucleotides encoding such binding protein can introduced into a host cell, such as a T cell, and the cell can be used in immunotherapy for treating various cancers.
unc-23unc-23) sequence that is associated with altered fibroblast growth factor receptor (FGFR) signaling. A subject having one or more such mutations in a BAG2 sequence can exhibit an increased FGFR signaling level relative to a reference FGFR signaling level, and can be predicted to be more responsive to inhibition of FGFR signaling with administration of one or more FGFR inhibitors to the subject. The disclosed methods are also useful for selectively identifying subjects who are expected to respond favorably to FGFR inhibition.
C12Q 1/6827 - Tests d’hybridation pour la détection de mutation ou de polymorphisme
A61K 38/18 - Facteurs de croissanceRégulateurs de croissance
C07K 14/71 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des facteurs de croissanceRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des régulateurs de croissance
C07K 16/22 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des facteurs de croissance
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
84.
VIRAL PARTICLE PRODUCER CELLS WITH LANDING PAD-INTEGRATED VIRAL VECTORS
Systems and methods to maintain a genotype-phenotype link during the production of viral particles are described. Cells are genetically modified to include a landing pad with an integrase attachment site within the cell's genome. The landing pad provides a site within the genome for a viral vector to reliably integrate. The landing pad allows for the integration of one viral vector per cell. Viral vectors include a barcode and a sequence encoding a protein of interest, with the barcode and protein of interest being associated through sequencing before integration into landing pads within cells.
Sequential immunization strategies to guide the maturation of antibodies against the human immunodeficiency virus (HIV) are described. The sequential immunization strategies utilize an HIV envelope protein (Env) that binds germline (gl) B cells as a first (prime) immunization and an Env with a functional glycosylated N276 as a second (boost) immunization. The sequential immunization strategies successfully elicit neutralizing antibodies against HIV.
The Trustees of the University of Pennsylvania (USA)
Fred Hutchinson Cancer Center (USA)
Inventeur(s)
Parhiz, Hamideh
Weissman, Drew
Kiem, Hans-Peter
Radtke, Stefan
Peterson, Christopher
Abrégé
The present invention relates to compositions and methods for effective delivery of an agent to a stem cell using a delivery vehicle, such as a lipid nanoparticle (LNP), comprising a CD90 targeting domain.
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
C12N 15/88 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p. ex. co-transformation utilisant la micro-encapsulation, p. ex. utilisant des vésicules liposomiques
87.
ANTIBODIES THAT BIND THE TUMOR (T) ANTIGEN OF MERKEL CELL POLYOMAVIRUS AND RELATED DIAGNOSTICS
Antibodies that bind the tumor (T) antigen of the Merkel cell polyomavirus are disclosed. The antibodies can be use used in cell-based immunotherapies, antibody-based therapies, diagnostics, and detection assays, among other uses. Related diagnostics are also described
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
G01N 33/533 - Production de composés immunochimiques marqués avec un marqueur fluorescent
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
88.
MOLECULAR SIGNATURES OF LONG-TERM COVID-19 AND TREATMENT THEREOF
In various embodiments, provided are immune response signatures that can be used for the diagnosis, monitoring, and treatment of long-term diseases and inflammatory disorders caused by viral infections. In some embodiments, the viral infection is SARS-CoV-2 infection. In some embodiments, the long-term disease is post-acute sequelae of SARS-CoV-2 infection (PASC).
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
The present disclosure relates to immunomodulatory fusion proteins containing an extracellular binding domain and an intracellular signaling domain, wherein binding of a target can generate a modulatory signal in a host cell, such as a T cell. The present disclosure also relates to uses of immune cells expressing such immunomodulatory fusion proteins to treat certain diseases, such as cancer or infectious disease.
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
A61K 40/22 - Immunosuppresseur ou induisant la tolérance
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
Mesothelin-specific binding proteins including mesothelin-specific T cell receptor (TCR) that specifically binds to mesothelin including. for example. in a complex with an MHC. Methods of making and using the mesothelin-specific binding proteins are also described, including the use of the mesothelin-specific binding protein in adoptive cell therapy.
The present disclosure provides compositions and methods for accurately detecting mutations by uniquely tagging double stranded nucleic acid molecules with dual cyphers such that sequence data obtained from a sense strand can be linked to sequence data obtained from an anti-sense strand when sequenced, for example, by massively parallel sequencing methods.
Methods for regulating aberrant glia-directed engulfment and active pruning of Neuronal Receptive Endings (NRE) are provided. Such methods comprise contacting a neuronal and/or glia cell with an effective amount of a composition which is effective in modulating at least one gene and/or protein associated with glia-directed engulfment and active pruning of Neuronal Receptive Endings. Such methods are useful in treating neurological disorders such as Parkinson's disease.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
36 - Services financiers, assurances et affaires immobilières
41 - Éducation, divertissements, activités sportives et culturelles
Produits et services
Apparel, namely, t-shirts, polo shirts, tank tops, long
sleeve shirts; athletic apparel, namely, shirts, hats, caps. Promoting public awareness about cancer and cancer research
(term considered too vague by the International Bureau – Rule 13 (2) (b) of the Regulations). Charitable fund raising. Organization of sports competitions; organizing and
conducting bicycling, walking, and running events;
organizing sporting events, namely, bicycling, walking, and
running events.
94.
METHODS AND COMPOSITIONS TO ENHANCE HUMORAL IMMUNITY TO REDUCE CYTOMEGALOVIRUS INFECTION AND REACTIVATION BY INTERFERON GAMMA INHIBITION
Compositions and methods for inhibiting viral reactivation and protecting against endothelial cell (EC) damage in a transplant subject. Methods include administering one or more compositions to the transplant subject; compositions can include one or more interferon-gamma (IFN-γ) antagonists, one or more interleukin 6 (IL-6) antagonists, one or more JAK/STAT signaling inhibitors, or any combination thereof. The compositions and methods inhibit cytomegalovirus (CMV) reactivation after tissue transplantation, increasing the safety and efficacy of tissue transplantation and reducing risk of complications due to CMV reactivation.
C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61P 31/20 - Antiviraux pour le traitement des virus ADN
A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe
95.
ANTI-FOLATE RECEPTOR CONJUGATE THERAPY FOR CANCER TREATMENT
Methods and compositions for providing a cytotoxic effect against FOLR-1 expressing cancers using antibody conjugates with binding specificity for folate receptor alpha (FOLR1) and its isoforms and homologs are provided. Examples of FOLR-1 expressing cancers include leukemias, ovarian cancer, breast cancer, bladder cancer, and lung cancer, among other cancers described herein.
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie
96.
COMBINATION THERAPIES FOR TREATMENT OF BCMA-RELATED CANCERS AND AUTOIMMUNE DISORDERS
The present disclosure relates to methods for using BCMA-specific binding molecules (such as a BCMA-specific chimeric antigen receptor or antibody) in combination with γ-secretase inhibitors, which can be done concurrently or sequentially, to treat or prevent a B-cell related proliferative disease, such as a cancer or autoimmune disease, or the like. A BCMA-specific binding molecule in combination with γ-secretase inhibitor can be used in, for example, adoptive immunotherapy.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
A61K 31/417 - Imidazole-alkylamines, p. ex. histamine, phentolamine
Antibodies that protect against respiratory viral infections including human parainfluenza viruses (HPIV), respiratory syncytial virus (RSV), and human metapneumovirus (HMPV) are described. Certain antibodies disclosed herein neutralize more than one virus (e.g., RSV and HMPV). The binding fragments of the antibodies can be engineered into numerous formats including those that provide simultaneous protection against multiple viruses.
In some embodiments, a computer-implemented method of detecting a presence of a predetermined fusion gene in a biological sample is provided. A computing system generates an alignment of a read sequence to a reference genome. The alignment includes a first alignment result and a second alignment result. The computing system determines a breakpoint location indicated by the first alignment result and the second alignment result, distances between coordinates of the breakpoint location and coordinates of one or more expected breakpoint locations associated with the predetermined fusion gene, a gap size value and an overlap size value. In response to determining that the gap size value is less than a gap size value threshold, the overlap size value is less than an overlap size value threshold, and the distances are less than a breakpoint distance threshold, the computing system generates an indication of the presence of the predetermined fusion gene.
G16B 20/00 - TIC spécialement adaptées à la génomique ou protéomique fonctionnelle, p. ex. corrélations génotype-phénotype
G16B 30/10 - Alignement de séquenceRecherche d’homologie
G16B 40/00 - TIC spécialement adaptées aux biostatistiquesTIC spécialement adaptées à l’apprentissage automatique ou à l’exploration de données liées à la bio-informatique, p. ex. extraction de connaissances ou détection de motifs
Systems and methods to simplify ex vivo gene therapy are described. The systems and methods provide ex vivo manufacturing of cells using target-cell enriching magnetic beads, vector-magnetic bead complexes, and a magnetic field. The present disclosure reduces the amount of required vector to 10 infectious particles per cell and does not require the use of transduction culture or cytokines. Cell manufacturing can be completed within one day, such that treated subjects do not require chemotherapy between cell collection and re-administration.
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
Provided herein are compositions comprising novel MHC class II T cell epitopes and method using thereof. In some embodiments, a composition described herein comprises an immunogenic polypeptide comprising an MHC class II T cell epitope and a target antigen. In some embodiments, the target antigen is a viral, bacterial, parasite or tumor specific antigen. In some embodiments, the target antigen comprises a virus, bacteria, parasite or tumor specific polypeptide. In some embodiments, the composition comprises a fusion polypeptide comprising the immunogenic polypeptide and the target polypeptide. Also provided are polynucleotides encoding the fusion polypeptide, and methods of administering a composition comprising the polynucleotide to a subject to elicit an immune response. In some embodiments, the polynucleotide is an RNA comprising modified ribonucleotides.
